| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary targets of Kinsenoside include the Nrf2 pathway and mitochondrial function. It rescues senescence and mitochondrial dysfunction in a Nrf2-dependent way. The compound also promotes glucose tolerance in both diabetic and normal healthy rats.
|
|---|---|
| ln Vitro |
In vitro, Kinsenoside has been shown to have antioxidant and anti-inflammatory activities. It rescues senescence and mitochondrial dysfunction in a Nrf2-dependent way. The compound's effects on cell viability and function have been demonstrated in various cell lines.
|
| ln Vivo |
In vivo, Kinsenoside promotes glucose tolerance in both diabetic and normal healthy rats. It also prevents bone loss in ovariectomized (OVX) mice. The compound's ability to repair beta cells in pancreatic islet injury has been demonstrated in animal models.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for Kinsenoside are not typically performed, as it does not have a single specific target. Its antioxidant activity can be assessed using cell-free assays such as DPPH radical scavenging. Its effects on mitochondrial function can be studied by measuring oxygen consumption and ATP production.
|
| Cell Assay |
In vitro cell-based assays for Kinsenoside are performed using various cell lines. Cells are treated with the compound, and cell viability, apoptosis, and mitochondrial function are assessed. The compound's effects on Nrf2 signaling and antioxidant gene expression are analyzed by Western blotting and qPCR.
|
| Animal Protocol |
In vivo animal experiments for Kinsenoside are conducted using rat and mouse models. The compound is administered orally, and its effects on glucose tolerance, pancreatic beta cell function, and bone loss are assessed. These studies confirm the compound's efficacy as a therapeutic agent for diabetes and osteoporosis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Kinsenoside indicate that it has a molecular weight of 264.23 and a molecular formula of C10H16O8. The CAS number is 151870-74-5. The IUPAC name is (4R)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-one. It is a powder with a purity of ≥98%.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for Kinsenoside are limited. As a natural compound, it is generally considered safe at moderate doses. However, its safety profile in the context of therapeutic use requires further evaluation. The compound is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
(3R)-5-oxotetrahydro-3-furanylβ-D-glucopyranoside is a glycoside. It has been reported that Hypericum husk, saffron, and Hypericum kauri contain hypericin, and relevant data are available.
Other information: Kinsenoside is a main active component isolated from plants of the genus Anoectochilus. It has antioxidant, anti-inflammatory, and anti-diabetic activities. The compound rescues senescence and mitochondrial dysfunction in a Nrf2-dependent way. Its CAS number is 151870-74-5. |
| Molecular Formula |
C10H16O8
|
|---|---|
| Molecular Weight |
264.2292
|
| Exact Mass |
264.084
|
| CAS # |
151870-74-5
|
| PubChem CID |
10422896
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
570.2±50.0 °C at 760 mmHg
|
| Flash Point |
226.2±23.6 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.584
|
| LogP |
-3.83
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
308
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1[C@H](COC1=O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O
|
| InChi Key |
MQEPWBMWFIVRPS-ZGSHZZHUSA-N
|
| InChi Code |
InChI=1S/C10H16O8/c11-2-5-7(13)8(14)9(15)10(18-5)17-4-1-6(12)16-3-4/h4-5,7-11,13-15H,1-3H2/t4-,5-,7-,8+,9-,10-/m1/s1
|
| Chemical Name |
(4R)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~378.46 mM)
DMSO : ~50 mg/mL (~189.23 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7846 mL | 18.9229 mL | 37.8458 mL | |
| 5 mM | 0.7569 mL | 3.7846 mL | 7.5692 mL | |
| 10 mM | 0.3785 mL | 1.8923 mL | 3.7846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
